<?xml version='1.0' encoding='utf-8'?>
<document id="30098042"><sentence text="Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers."><entity charOffset="57-66" id="DDI-PubMed.30098042.s1.e0" text="pimodivir" /><entity charOffset="203-214" id="DDI-PubMed.30098042.s1.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30098042.s1.e0" e2="DDI-PubMed.30098042.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s1.e0" e2="DDI-PubMed.30098042.s1.e1" /></sentence><sentence text="The aim of this study was to evaluate the drug-drug interaction between pimodivir, a novel, non-nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasibility of this combination therapy"><entity charOffset="207-218" id="DDI-PubMed.30098042.s2.e0" text="oseltamivir" /></sentence><sentence text=" Furthermore, single- and multiple-dose pharmacokinetics and safety of pimodivir in healthy volunteers were assessed" /><sentence text="" /><sentence text="In Part 1 of this open-label Phase 1 study, healthy volunteers (n = 18) were randomized to one of six cross-over treatment sequences, each comprising administration of oseltamivir 75 mg or pimodivir 600 mg or combination thereof twice daily on Days 1-4, followed by a single morning dose on Day 5"><entity charOffset="168-179" id="DDI-PubMed.30098042.s5.e0" text="oseltamivir" /><entity charOffset="189-198" id="DDI-PubMed.30098042.s5.e1" text="pimodivir" /><pair ddi="false" e1="DDI-PubMed.30098042.s5.e0" e2="DDI-PubMed.30098042.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s5.e0" e2="DDI-PubMed.30098042.s5.e1" /></sentence><sentence text=" Between each treatment session, there was a minimum 5-day washout period" /><sentence text=" In Part 2, healthy volunteers (n = 16) randomly received pimodivir 600 mg or placebo (3:1) twice daily on Days 1-9, followed by a single morning dose on Day 10" /><sentence text=" Pharmacokinetics of pimodivir, oseltamivir and oseltamivir carboxylate, and safety were assessed"><entity charOffset="21-30" id="DDI-PubMed.30098042.s8.e0" text="pimodivir" /><entity charOffset="32-43" id="DDI-PubMed.30098042.s8.e1" text="oseltamivir" /><entity charOffset="48-71" id="DDI-PubMed.30098042.s8.e2" text="oseltamivir carboxylate" /><pair ddi="false" e1="DDI-PubMed.30098042.s8.e0" e2="DDI-PubMed.30098042.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s8.e0" e2="DDI-PubMed.30098042.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s8.e0" e2="DDI-PubMed.30098042.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30098042.s8.e1" e2="DDI-PubMed.30098042.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s8.e1" e2="DDI-PubMed.30098042.s8.e2" /></sentence><sentence text="" /><sentence text="In Part 1, co-administration of pimodivir with oseltamivir increased the Cmax of pimodivir by 31% (90% CI: 0"><entity charOffset="32-41" id="DDI-PubMed.30098042.s10.e0" text="pimodivir" /><entity charOffset="47-58" id="DDI-PubMed.30098042.s10.e1" text="oseltamivir" /><entity charOffset="81-90" id="DDI-PubMed.30098042.s10.e2" text="pimodivir" /><entity charOffset="103-105" id="DDI-PubMed.30098042.s10.e3" text="CI" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e0" e2="DDI-PubMed.30098042.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e0" e2="DDI-PubMed.30098042.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e0" e2="DDI-PubMed.30098042.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e0" e2="DDI-PubMed.30098042.s10.e3" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e1" e2="DDI-PubMed.30098042.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e1" e2="DDI-PubMed.30098042.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e1" e2="DDI-PubMed.30098042.s10.e3" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e2" e2="DDI-PubMed.30098042.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30098042.s10.e2" e2="DDI-PubMed.30098042.s10.e3" /></sentence><sentence text="92-1" /><sentence text="85) with no change in Cmin or AUC12h " /><sentence text=" Pimodivir had no effect on oseltamivir or oseltamivir carboxylate pharmacokinetics"><entity charOffset="1-10" id="DDI-PubMed.30098042.s13.e0" text="Pimodivir" /><entity charOffset="28-39" id="DDI-PubMed.30098042.s13.e1" text="oseltamivir" /><entity charOffset="43-66" id="DDI-PubMed.30098042.s13.e2" text="oseltamivir carboxylate" /><pair ddi="false" e1="DDI-PubMed.30098042.s13.e0" e2="DDI-PubMed.30098042.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s13.e0" e2="DDI-PubMed.30098042.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s13.e0" e2="DDI-PubMed.30098042.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30098042.s13.e1" e2="DDI-PubMed.30098042.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30098042.s13.e1" e2="DDI-PubMed.30098042.s13.e2" /></sentence><sentence text=" In Part 2, after single- and multiple-dose administration of pimodivir, there was a 1"><entity charOffset="62-71" id="DDI-PubMed.30098042.s14.e0" text="pimodivir" /></sentence><sentence text="2- and 1" /><sentence text="8-fold increase in Cmax and AUC12h , respectively, between Day 1 and Day 10" /><sentence text=" The most frequently reported treatment-emergent adverse event was diarrhoea (n = 7 each in Part 1 and 2)" /><sentence text="" /><sentence text="Combination treatment with pimodivir and oseltamivir in healthy volunteers showed no clinically relevant drug-drug interactions"><entity charOffset="27-36" id="DDI-PubMed.30098042.s19.e0" text="pimodivir" /><entity charOffset="41-52" id="DDI-PubMed.30098042.s19.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30098042.s19.e0" e2="DDI-PubMed.30098042.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s19.e0" e2="DDI-PubMed.30098042.s19.e1" /></sentence><sentence text=" No safety concerns were identified with pimodivir 600 mg twice daily alone or in combination with oseltamivir 75 mg twice daily"><entity charOffset="41-50" id="DDI-PubMed.30098042.s20.e0" text="pimodivir" /><entity charOffset="99-110" id="DDI-PubMed.30098042.s20.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30098042.s20.e0" e2="DDI-PubMed.30098042.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30098042.s20.e0" e2="DDI-PubMed.30098042.s20.e1" /></sentence><sentence text="" /></document>